A new market research report by Transparency Market Research, titled “Learning Disability Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” is a detailed evaluation that aids in recognizing the major unmet requirements in the market from 2014 to 2020. The prime developments poised to take place in the learning disability treatment market in the coming years have also been elaborated under this study.
The current competition within this market coupled with an analysis on the competitors in the market is also a key part of this study. An insightful review on the key industry challenges, drivers, challenges, restraints, and trends is also a key part covered under this study.
Learning disability is a term used for describing particular types of learning problems. This kind of disability can result in a person having trouble in learning and utilizing certain skills. The disorder occurs at an early age and is usually detected at 5 years of age. In this kind of disability, the brain of the patient is unable to store, receive, and respond to information. It isn’t a single disorder but a group of disorders that may include dyscalculia, dyslexia, dysgraphia, attention-deficit hyperactivity disorder (ADHD), dyspraxia, visual and auditory processing disorders. The common skills affected are listening, reading, speaking, writing, and reasoning.
There are a number of learning disability therapies introduced globally. These are solution-focused counseling, cognitive behavioral therapy, and social skill groups to help children with learning disabilities. Due to the unknown cause of these disabilities, there are as of now no medicines to provide a core treatment for learning disabilities.
However, some medicines are still being prescribed for the management and treatment of ADHD in patients. There are three major categories in which these medicines can be segmented, namely non-stimulants, stimulants, and other medicines. Of these, stimulants refer to psychoactive drugs focused on bringing temporary improvements in either physical or mental actions or both. Stimulants are the most commonly utilized and the best studied medicines so far for the treatment of ADHD within the market for learning disability treatment.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2478
Among the commonly utilized stimulants are: Methylphenidate (ritalin, concerta), dexmethylphenidate (focalin), amphetamine/dextroamphetamine (adderall, dexedrine, dextrostat), lisdexamfetamine (vyvanse). The other medicines utilized for learning disability treatment are antidepressants – bupropion (wellbutrin), tricyclics – imipramine (tofranil), nortriptyline (pamelor, aventyl), desipramine (norpramin), and alpha-2 agonists – clondine (catapres), guanfacine (tenex).
Geographically, Europe and North America are currently leading the global learning disability treatment market owing to the rising count of medications for ADHD and soaring count of schools for the children suffering from learning disabilities. On the other hand, Asia Pacific is also a rapidly developing market for learning disability treatment due to the increasing initiatives taken by governments for establishing special schools within this region.
Forest Laboratories, Inc., Pfizer, Inc., Novartis AG, Shire Plc., and Eli Lilly and Company, among others are the major players in the market, as per this study.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453